Analysts Set Expectations for PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Pliant Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($4.46) per share for the year. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

Separately, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Stock Down 1.2 %

Shares of PLRX stock opened at $11.07 on Wednesday. The business’s fifty day moving average is $13.29 and its 200 day moving average is $13.07. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. Pliant Therapeutics has a twelve month low of $10.22 and a twelve month high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last posted its earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.04.

Hedge Funds Weigh In On Pliant Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. American Century Companies Inc. increased its position in shares of Pliant Therapeutics by 18.1% during the second quarter. American Century Companies Inc. now owns 74,113 shares of the company’s stock valued at $797,000 after acquiring an additional 11,351 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Pliant Therapeutics by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 305,322 shares of the company’s stock worth $3,282,000 after purchasing an additional 5,152 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Pliant Therapeutics by 233.8% in the second quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock worth $2,724,000 after purchasing an additional 177,469 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in shares of Pliant Therapeutics by 39.1% during the second quarter. Ensign Peak Advisors Inc now owns 35,368 shares of the company’s stock valued at $380,000 after purchasing an additional 9,950 shares in the last quarter. Finally, Great Point Partners LLC boosted its position in shares of Pliant Therapeutics by 42.4% during the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after buying an additional 785,000 shares during the last quarter. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.